1.40

4.48% 0.06

Pacific Biosciences Of California Inc (PACB)

Panoramica Notizia Cronologia dei prezzi Catena di opzioni Financials Perché PACB Giù? Forum Previsione

Precedente Chiudi:

$1.34

Aprire:

$1.36

Volume 24 ore:

4.31M

Relative Volume:

0.72

Capitalizzazione di mercato:

$434.84M

Reddito:

$160.03M

Utile/perdita netta:

$-128.58M

Rapporto P/E:

-3.2802

EPS:

-0.4268

Flusso di cassa netto:

$-121.21M

1 W Prestazione:

+3.70%

1M Prestazione:

+21.74%

6M Prestazione:

-25.53%

1 anno Prestazione:

+6.87%

Intervallo 1D:

$1.36

$1.43

Intervallo di 1 settimana:

$1.30

$1.45

Portata 52W:

$1.09

$2.73

Pacific Biosciences Of California Inc Stock (PACB) Company Profile

Nome

Pacific Biosciences Of California Inc

Settore

Healthcare (1104)

Industria

Medical Devices (141)

Telefono

650-521-8000

Indirizzo

1305 O'BRIEN DRIVE, MENLO PARK, CA

Dipendente

485

Cinguettio

@pacbio

Prossima data di guadagno

2026-08-06

Ultimi documenti SEC

PACB's Discussions on Twitter

Compare PACB vs ABT, SYK, MDT, BSX, EW

Azioni	Prezzo	Cap. di mercato	Reddito	Reddito netto	Flusso di cassa	EPS
PACB Pacific Biosciences Of California Inc	1.40	434.84M	160.03M	-128.58M	-121.21M	-0.4268
ABT Abbott Laboratories	88.41	153.99B	45.13B	6.28B	7.38B	3.5895
SYK Stryker Corp	307.80	118.00B	25.27B	3.34B	4.57B	8.6334
MDT Medtronic Plc	79.34	101.86B	36.36B	4.84B	5.43B	3.7212
BSX Boston Scientific Corp	45.29	67.32B	20.62B	3.56B	3.48B	2.3847
EW Edwards Lifesciences Corp	87.36	50.30B	6.30B	1.07B	1.09B	1.8406

Pacific Biosciences Of California Inc Stock (PACB) Upgrades & Downgrades

Data	Azione	Analista	Modifica della valutazione
2026-03-06	Downgrade	Barclays	Equal Weight → Underweight
2024-11-11	Downgrade	UBS	Buy → Neutral
2024-06-03	Ripresa	Jefferies	Buy
2024-04-22	Downgrade	JP Morgan	Overweight → Neutral
2024-04-18	Downgrade	Goldman	Buy → Neutral
2023-12-14	Iniziato	Guggenheim	Neutral
2023-12-14	Iniziato	Stephens	Overweight
2023-12-13	Iniziato	Wolfe Research	Peer Perform
2023-11-17	Aggiornamento	UBS	Neutral → Buy
2023-10-31	Aggiornamento	Cantor Fitzgerald	Neutral → Overweight
2023-09-28	Iniziato	Bernstein	Outperform
2023-07-05	Ripresa	JP Morgan	Overweight
2023-06-30	Iniziato	Goldman	Buy
2023-05-10	Iniziato	Barclays	Equal Weight
2023-03-31	Aggiornamento	TD Cowen	Market Perform → Outperform
2023-02-02	Iniziato	UBS	Neutral
2023-01-20	Downgrade	Cantor Fitzgerald	Overweight → Neutral
2023-01-05	Iniziato	Scotiabank	Sector Outperform
2022-01-21	Ripresa	Cantor Fitzgerald	Overweight
2022-01-06	Ripresa	Piper Sandler	Neutral
2021-10-15	Ripresa	Cowen	Market Perform
2021-09-27	Iniziato	Canaccord Genuity	Buy
2021-02-11	Aggiornamento	Piper Sandler	Neutral → Overweight
2020-11-03	Downgrade	Piper Sandler	Overweight → Neutral
2020-10-02	Aggiornamento	JP Morgan	Neutral → Overweight
2020-09-09	Iniziato	Morgan Stanley	Equal-Weight
2020-06-02	Ripresa	Cantor Fitzgerald	Overweight
2020-03-09	Ripresa	Cantor Fitzgerald	Overweight
2019-10-15	Aggiornamento	Piper Jaffray	Neutral → Overweight
2019-04-02	Downgrade	Stephens	Overweight → Equal-Weight
2018-10-19	Iniziato	Cowen	Outperform
2017-11-03	Downgrade	First Analysis Sec	Overweight → Equal-Weight
2017-09-28	Downgrade	CL King	Buy → Neutral
2016-11-03	Reiterato	Cantor Fitzgerald	Buy
2016-06-27	Iniziato	CL King	Buy
2016-04-15	Iniziato	First Analysis Sec	Overweight
2016-02-04	Downgrade	Piper Jaffray	Overweight → Neutral
2016-01-04	Reiterato	Cantor Fitzgerald	Buy
2015-10-23	Aggiornamento	Piper Jaffray	Neutral → Overweight
2015-08-27	Iniziato	Cantor Fitzgerald	Buy
2015-02-04	Reiterato	Maxim Group	Buy
2013-09-26	Reiterato	Maxim Group	Buy
2013-01-14	Reiterato	Maxim Group	Buy

Mostra tutto

Pacific Biosciences Of California Inc Borsa (PACB) Ultime notizie

Jun 19, 2026